MET and neoplasm: miR-199a can downregulate mTOR (mechanistic Target of Rapamycin), c-MET (protein encoded by the MET gene), and its downstream effector ERK2, thus inhibiting cell proliferation, motility, and the invasive capabilities of tumor cells [22,23].